Arrowhead to Present at Nanobusiness Alliance Conference
PASADENA, California – April 17, 2007 – Arrowhead Research Corporation (Nasdaq: ARWR), announced that John C. Miller, Vice President, Business Development, will present “Bringing Nanotech to the Public Markets” at the Sixth Annual NanoBusiness Alliance Conference in New York City today at 4:00 pm.
Mr. Miller’s presentation will focus on Arrowhead’s acquisition, financial and value building strategies for its growing portfolio of emerging nanotechnology companies. Currently, Arrowhead operates four majority-owned subsidiaries commercializing nanotech products including anti-cancer drugs, RNAi therapeutics, carbon-based electronics and compound semiconductor materials. In particular, he will discuss the progress of Unidym, Inc., an Arrowhead subsidiary commercializing carbon nanotube electronics, including transparent flexible electrodes and thin film transistors.
Mr. Miller is the primary architect of Arrowhead’s strategy related to carbon-based electronics. Through a wholly owned subsidiary, NanoPolaris, Arrowhead began by exclusively licensing key patents and patent applications covering carbon nanotube technologies developed at eight leading universities. In June 2006, NanoPolaris acquired the assets of Unidym, Inc., a UCLA based start-up commercializing new carbon-based electronic products and changed its name to Unidym. Unidym has recently announced a merger with Carbon Nanotechnologies, Inc., which holds the leading portfolio of intellectual property in carbon nanotube technology and is the world’s largest manufacturer of carbon nanotubes. The combined company will continue to develop products internally and with industry partners and, as well as an out licensing program.
About Arrowhead Research Corporation
Arrowhead Research Corporation (www.arrowheadresearch.com) is a publicly-traded nanotechnology company commercializing new technologies in the areas of life sciences, electronics, and energy. Arrowhead is building value for shareholders through the progress of majority owned subsidiaries founded on nanotechnologies originally developed at universities. The company works closely with universities to source early stage deals and to generate rights to intellectual property covering promising new nanotechnologies. Currently, Arrowhead has four subsidiaries commercializing nanotech products and applications, including anti-cancer drugs, RNAi therapeutics, carbon-based electronics and compound semiconductor materials.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K and 10-K/A, recent and forthcoming Quarterly Reports on Form 10-Q and 10-Q/A, recent Current Reports on Forms 8-K and 8-K/A, our Registration Statement on Form S-3, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.
Contacts
Virginia Dadey; Vice President, Investor Relations
Telephone: 212.541.3707
Email: vdadey@arrowres.com